CBG, CBD, and Mood: The Dopamine and Serotonin Connections

Most cannabinoid mood research is framed around anxiety — and for good reason, since CBD's human anxiety evidence is the most developed in the cannabinoid literature, and CBG's first controlled trial used anxiety as its primary outcome measure. But anxiety is only one dimension of mood. Motivation, reward processing, emotional resilience, and the general hedonic tone of daily experience involve overlapping but distinct neural systems — primarily the dopaminergic and serotonergic pathways — and the endocannabinoid system's relationship to those systems goes beyond the HPA axis and cortisol mechanisms that anchor most cannabinoid stress coverage.

This article covers the ECS-dopamine and ECS-serotonin connections that are documented in preclinical research, what they suggest about CBG and CBD's mechanisms in mood-relevant neural systems, and where the evidence limits are honestly drawn.

The Dopamine System and the ECS

Dopamine is the primary neurotransmitter of the brain's reward, motivation, and reinforcement systems. Two dopaminergic pathways are most relevant to mood: the mesolimbic pathway, which projects from the ventral tegmental area (VTA) to the nucleus accumbens and is involved in reward processing, motivation, and the experience of pleasure; and the mesocortical pathway, which projects from the VTA to the prefrontal cortex and is involved in emotional regulation, decision-making, and cognitive aspects of mood.

CB1 receptors are expressed throughout both pathways — in the VTA, in the nucleus accumbens, and in the prefrontal cortex. Their presence at these sites is not incidental. Endocannabinoid signalling in the mesolimbic pathway modulates dopamine release through presynaptic inhibition at GABAergic interneurons — the local inhibitory neurons that normally suppress VTA dopamine neuron firing. When CB1 receptors on these interneurons are activated, their inhibitory output is reduced, allowing dopamine neurons to fire more freely. This disinhibition mechanism gives the ECS an indirect but significant influence over dopamine tone in reward circuits.

The practical consequence of this architecture is that endocannabinoid tone influences motivation, reward sensitivity, and the baseline capacity for positive affect — not through direct dopamine release, but through the GABAergic gating that regulates it. Reduced ECS tone, whether from chronic stress, aging, or other factors that suppress endocannabinoid production, would be expected to reduce this disinhibitory effect and lower dopamine tone in mesolimbic circuits. Increased ECS tone has the opposite effect.

CBG's Dopamine-Relevant Mechanisms

CBG does not act directly on dopamine receptors. Its dopamine-relevant mechanisms operate through adjacent systems. The most documented is CBG's alpha-2 adrenoceptor agonism, covered in detail in the alpha-2 adrenoceptor article. The noradrenergic system — through the locus coeruleus projection to the prefrontal cortex and limbic system — interacts closely with mesocortical dopamine signalling. Alpha-2 agonism reduces noradrenaline release at these projections, modulating the arousal state that sets the context for dopamine-mediated mood and motivation processing.

CBG's CB1 partial agonism at the mesolimbic level is directly relevant to dopamine tone through the disinhibition mechanism described above. As a partial agonist — activating CB1 without the full efficacy of anandamide — CBG participates in the endocannabinoid modulation of GABAergic interneurons in VTA circuits without producing the receptor desensitisation that full agonists can cause with repeated dosing.

CBG's GABA reuptake inhibition adds a third relevant mechanism. GABA is the primary inhibitory neurotransmitter in the brain, and its availability at multiple points in the reward circuitry influences the balance between excitation and inhibition that determines mood tone. Increased GABA availability through reuptake inhibition does not operate exclusively in the dopamine system, but its effects in limbic and cortical circuits that interact with mesolimbic dopamine pathways are mechanistically relevant.

The Serotonin System and the ECS

Serotonin — synthesised primarily in the dorsal raphe nucleus and projecting widely through the brain — is the neurotransmitter most centrally associated with mood regulation in clinical pharmacology. The majority of pharmaceutical antidepressants target the serotonin system, either by inhibiting its reuptake or by acting on serotonin receptors. The endocannabinoid system's relationship to the serotonin system is bidirectional and well-documented in preclinical research.

CB1 receptors are expressed in the dorsal raphe nucleus and on serotonergic projection neurons. Endocannabinoid signalling at these sites modulates serotonin release in target regions. Conversely, serotonin receptor activation — particularly 5-HT2A and 5-HT2C receptors — modulates endocannabinoid production in postsynaptic neurons through phospholipase C activation and the resulting generation of 2-AG precursors. The two systems regulate each other through multiple feedback loops.

Anandamide and 2-AG production in cortical and limbic neurons is partly dependent on serotonergic input, meaning that chronic serotonin system dysregulation — as occurs in sustained depression or chronic stress — alters the endocannabinoid environment in mood-relevant brain regions. This bidirectionality suggests that the ECS and the serotonin system should be understood as interacting partners in mood regulation rather than independent parallel systems.

CBD's 5-HT1A Partial Agonism

CBD's most directly documented mechanism in the serotonin system is partial agonism at the 5-HT1A receptor — one of the major serotonin receptor subtypes with established roles in anxiety, mood, and stress responses. This was first documented in a 2005 study by Russo et al. in a radioligand binding assay and has been replicated across multiple subsequent in vitro and in vivo studies.

The 5-HT1A receptor is the primary target of buspirone, an anxiolytic medication used clinically for generalised anxiety disorder, and is involved in the delayed therapeutic effects of SSRI antidepressants — SSRIs' long-term desensitisation of 5-HT1A autoreceptors in the raphe nucleus is one proposed mechanism for their gradual mood-stabilising effects. CBD's partial agonism at 5-HT1A represents a direct serotonergic mechanism — not a secondary consequence of endocannabinoid modulation — and is the most pharmacologically clean connection between a phytocannabinoid and the serotonin system currently in the literature.

The functional significance of CBD's 5-HT1A activity in vivo has been explored in rodent models. The anxiolytic effects of CBD in elevated plus maze and forced swim test paradigms are attenuated by 5-HT1A antagonists, suggesting that at least part of CBD's observed effect in these models is mediated through serotonergic activity. This does not establish clinical relevance for human mood or anxiety outcomes — the rodent model to human translation remains a significant inferential step — but it provides a mechanistic rationale for CBD's human anxiety findings that goes beyond FAAH inhibition and anandamide availability alone.

The FAAH-Serotonin Interaction

CBD's FAAH inhibition mechanism and its 5-HT1A agonism interact in ways that compound the serotonergic relevance. Anandamide — whose availability is increased by FAAH inhibition — has its own documented activity at 5-HT1A receptors, acting as a partial agonist through a mechanism related to but distinct from CBD's direct receptor interaction. Elevated anandamide from FAAH inhibition therefore produces both increased CB1 activation and increased 5-HT1A activation, giving CBD's primary mechanism a secondary serotonergic consequence.

This interaction helps explain why CBD's effects in human anxiety studies are not fully accounted for by CB1-mediated mechanisms alone — the receptor profile is broader, and the serotonergic component is a meaningful part of the pharmacological picture. It also provides a rationale for why CBD's human evidence is more consistent in anxiety contexts than in pure pain contexts, where serotonin's modulatory role is less central.

Mood Beyond Anxiety — What the Mechanistic Picture Suggests

The dopaminergic and serotonergic connections described above suggest that CBG and CBD's mechanisms extend into mood regulation systems beyond the HPA axis and acute anxiety circuitry that most cannabinoid research addresses. What that extension means in clinical terms requires more precision than the preclinical literature currently supports.

Low dopamine tone in mesolimbic circuits is associated with anhedonia — the reduced capacity for pleasure and reward that is one of the diagnostic features of depression. The ECS-dopamine disinhibition mechanism suggests that endocannabinoid tone is a modulator of this capacity, and that CBG's mechanisms in the dopaminergic system are relevant to the motivational and hedonic dimensions of mood rather than only the anxious arousal dimension. This is a mechanistically grounded inference — not a clinical claim — but it is a meaningful extension of the evidence base beyond anxiety.

CBD's 5-HT1A agonism similarly suggests relevance to the baseline mood regulation functions of the serotonin system — not only to acute anxiety responses. Whether this translates to detectable effects on mood outcomes in human populations, at what doses, and under what conditions, is not established by current evidence. The mechanistic picture is coherent and interesting; the clinical extrapolation remains premature.